Atuveciclib (Synonyms: BAY-1143572)

Name: Atuveciclib
Brand: MedChemExpress
SKU: HY-12871B
Rating: 5.0 (10 reviews)

Cat. No.: HY-12871B Purity: 99.75% ee.: 99.10%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC₅₀ of 13 nM.

For research use only. We do not sell to patients.

Atuveciclib Chemical Structure

CAS No. : 2923012-24-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Atuveciclib:

Atuveciclib Racemate In-stock
Atuveciclib S-Enantiomer In-stock

10 Publications Citing Use of MCE Atuveciclib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC₅₀ of 13 nM^[1].

IC₅₀ & Target^[1]

CDK9/CycT1

13 nM (IC₅₀)

CDK9/CycT1(h)

6 nM (IC₅₀)

CDK3/CycE(h)

890 nM (IC₅₀)

CDK2/CycE(h)

1000 nM (IC₅₀)

CDK1/CycB(h)

1100 nM (IC₅₀)

CDK5/p35(h)

1600 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.34 μM Compound: BAY-1143572	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
A549	IC₅₀	3.29 μM Compound: BAY-1143572	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
B16	IC₅₀	1.47 μM Compound: BAY-1143572	Antiproliferative activity against mouse B16 cells incubated for 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
BT-549	IC₅₀	2.01 μM Compound: (+)-BAY-1143572	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth	[PMID: 37837671]
HCT-116	IC₅₀	0.26 μM Compound: BAY-1143572	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
HCT-116	IC₅₀	2.94 μM Compound: BAY-1143572	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
HeLa	IC₅₀	1500 nM Compound: 50; BAY-1143572	Antiproliferative activity against human HeLa cells incubated for 96 hrs by crystal violet staining assay Antiproliferative activity against human HeLa cells incubated for 96 hrs by crystal violet staining assay	[PMID: 32870008]
HepG2	IC₅₀	2.7 μM Compound: BAY-1143572	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
L02	IC₅₀	2.55 μM Compound: BAY-1143572	Antiproliferative activity against human L02 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
MCF7	IC₅₀	5.52 μM Compound: BAY-1143572	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
MDA-MB-231	IC₅₀	1.32 μM Compound: (+)-BAY-1143572	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth	[PMID: 37837671]
MDA-MB-436	IC₅₀	0.63 μM Compound: (+)-BAY-1143572	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth	[PMID: 37837671]
MOLM-13	IC₅₀	0.2 μM Compound: BAY-1143572	Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
MOLM-13	IC₅₀	310 nM Compound: 3	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo reagent assay Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo reagent assay	[PMID: 38564299]
MV4-11	IC₅₀	0.56 μM Compound: BAY-1143572	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
NCI-H1975	IC₅₀	0.72 μM Compound: BAY-1143572	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
NCI-H1975	IC₅₀	1.08 μM Compound: BAY1143572	Antiproliferative activity against human Osimertinib-resistant NCI-H1975 cell incubated for 72 hrs by MTT assay Antiproliferative activity against human Osimertinib-resistant NCI-H1975 cell incubated for 72 hrs by MTT assay	[PMID: 37870244]
PANC-1	IC₅₀	0.11 μM Compound: BAY-1143572	Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
Sf9	IC₅₀	1000 nM Compound: BAY-1143572	Inhibition of recombinant GST-tagged human CDK2/cyclin-E expressed in sf9 cels using biotin-Ttds-YISPLKSPYKISEG as substrate preincubated for 15 mins followed by substrate addition and measured after 25 mins in presence of ATP by TR-FRET assay Inhibition of recombinant GST-tagged human CDK2/cyclin-E expressed in sf9 cels using biotin-Ttds-YISPLKSPYKISEG as substrate preincubated for 15 mins followed by substrate addition and measured after 25 mins in presence of ATP by TR-FRET assay	[PMID: 31238183]

In Vitro

Positive transcription elongation factor b (PTEFb) is a heterodimer of CDK9 and one of four cyclin partners, cyclin T1, cyclin K, cyclin T2a or cyclin T2b. Atuveciclib (BAY-1143572) demonstrates potent antiproliferative activity against HeLa cells (IC₅₀=920 nM) and MOLM-13 cells (IC₅₀=310 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In vivo efficacy studies in the MOLM-13 xenograft model in mice, Atuveciclib (BAY-1143572) demonstrates great potency and high antitumor efficacy. Daily administration of Atuveciclib (BAY-1143572) at 6.25 or 12.5 mg/kg results in a dose-dependent antitumor efficacy with a treatment-to-control (T/C) ratio of 0.64 and 0.49, respectively (p<0.001). In a separate experiment with a higher daily dose of 20 or 25 mg/kg Atuveciclib (BAY-1143572), antitumor efficacy with a T/C ratio of 0.41 and 0.31, respectively, is observed (p<0.001). The 25 mg/kg once daily dose is the maximum tolerated dose in nude mice. Furthermore, Atuveciclib (BAY-1143572) administered at 25 or 35 mg/kg, three days on / two days off, results in a T/C ratio of 0.33 and 0.20, respectively (p<0.001). Treatment with Atuveciclib (BAY-1143572) is well-tolerated, as demonstrated by less than 10 % mean body weight reduction throughout the study. In an in vivo pharmacokinetic study in rats, Atuveciclib (BAY-1143572) shows low blood clearance (CL_b 1.1 L/kg per hour)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

387.43

Formula

C₁₈H₁₈FN₅O₂S

CAS No.

2923012-24-0

Appearance

Solid

Color

White to off-white

SMILES

N=[S@](CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (258.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5811 mL	12.9056 mL	25.8111 mL
5 mM	0.5162 mL	2.5811 mL	5.1622 mL
10 mM	0.2581 mL	1.2906 mL	2.5811 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.75% ee.: 99.10%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (247 KB) HNMR (183 KB) NP-HPLC (171 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793. [Content Brief]

Cell Assay ^[1]	HeLa human cervical tumor cells (CCL-2) and MOLM-13 human acute myeloid leukemia cells (ACC 554) are propagated under the suggested growth conditions in a humidified 37°C incubator. Proliferation assays are conducted in 96-well plates at densities of 3000 (HeLa) and 5000 (MOLM-13) cells per well in the growth medium containing 10 % fetal calf serum (FCS). Cells are treated in quadruplicate with serial dilutions of test compounds (e.g., Atuveciclib (BAY-1143572)) for 96 h. Relative cell numbers are quantified by crystal violet staining (HeLa) or CellTitre-Glo Luminescent Cell Viability Assay (MOLM-13). IC₅₀ values are determined by means of a four-parameter fit on measurement data which are normalized to vehicle (DMSO) treated cells (=100 %) and measurement readings taken immediately before compound exposure (=0 %)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice and Rats^[1] For the acute myeloid leukemia (AML) mouse model, 2×10⁶ MOLM-13 human AML cells are inoculated subcutaneously to the left flank of female NMRI nu/nu mice (18-21 g, 5-6 weeks). For the AML model in rats, 2×10⁶ MV4-11 human AML cells are inoculated subcutaneously to the left flank of female athymic nude rats (160-200 g, 5-6 weeks). Animals are stratified into treatment and control groups (n=8-13/group for mice, n=12/group for rats) based on primary tumor size. Treatments are started 3-13 days after tumor cell inoculation when the average tumor sizes are 23-38 mm² and 43 mm² for mice and rats, respectively. The 20 and 25 mg/kg once daily dose is for nude mice. Furthermore, Atuveciclib (BAY-1143572) administered at 25 or 35 mg/kg, three days on/two days off. BAY-1143572 is administered daily oral administration of Atuveciclib (BAY-1143572) at 12 mg/kg for rats. Unless otherwise indicated, all treatments are administered orally (p.o.) and are continued until the end of the experiment. Body weight and tumor areas (longest diameter multiplied by its perpendicular) measured by caliper are determined at least twice weekly. T/C ratios are calculated by dividing the mean tumor area of the treatment group by the mean tumor area of the vehicle group at the time point when the vehicle group is sacrificed^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5811 mL	12.9056 mL	25.8111 mL	64.5278 mL
	5 mM	0.5162 mL	2.5811 mL	5.1622 mL	12.9056 mL
	10 mM	0.2581 mL	1.2906 mL	2.5811 mL	6.4528 mL
	15 mM	0.1721 mL	0.8604 mL	1.7207 mL	4.3019 mL
	20 mM	0.1291 mL	0.6453 mL	1.2906 mL	3.2264 mL
	25 mM	0.1032 mL	0.5162 mL	1.0324 mL	2.5811 mL
	30 mM	0.0860 mL	0.4302 mL	0.8604 mL	2.1509 mL
	40 mM	0.0645 mL	0.3226 mL	0.6453 mL	1.6132 mL
	50 mM	0.0516 mL	0.2581 mL	0.5162 mL	1.2906 mL
	60 mM	0.0430 mL	0.2151 mL	0.4302 mL	1.0755 mL
	80 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8066 mL
	100 mM	0.0258 mL	0.1291 mL	0.2581 mL	0.6453 mL

Atuveciclib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Atuveciclib2923012-24-0BAY-1143572BAY1143572BAY 1143572CDKCyclin dependent kinaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Atuveciclib (Synonyms: BAY-1143572)

Customer Review

Other Forms of Atuveciclib:

Atuveciclib Related Antibodies

10 Publications Citing Use of MCE Atuveciclib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Atuveciclib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Atuveciclib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report